Urakçı Zuhat, Kaplan Muhammet Ali, Oruç Zeynep, Gümüş Mahmut, Uncu Doğan, Ebinç Senar, Özkan Metin, Geredeli Çağlayan, Elkıran Emin Tamer, Girgin Sadullah
Department of Medical Oncology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye.
Department of Medical Oncology, Medeniyet University, 34720 Istanbul, Türkiye.
Ann Ital Chir. 2024;95(6):1170-1177. doi: 10.62713/aic.3319.
In early-stage breast cancer, the axillary lymph nodes play a crucial role in determining the prognosis of the disease. The rate of lymph node involvement might be a more valuable prognostic factor than the number of positive lymph nodes. Therefore, we aimed to evaluate whether the lymph node ratio (LNR) is a superior prognostic indicator compared to the pathologic lymph node count in early-stage disease.
We included 3053 non-metastatic, lymph node-positive breast cancer patients who were treated and followed at 6 medical oncology centers in Türkiye between 2004-2018. Based on LNR, patients were classified into three risk groups: high (>0.65), intermediate (0.21-0.65), and low (≤0.20).
Classification of patients according to the TNM8 system based on the number of positive lymph nodes revealed that pathologic lymph node count (pN)1 accounted for 49.0% (n = 1495), pN2 for 30.0% (n = 917), and pN3 for 21.0% (n = 641). Based on the LNR risk group, the low-risk group accounted for 45.4% (n = 1385), intermediate for 36.2% (n = 1105), and high for 18.4% (n = 563) of the total patients. For the entire patient cohort, the 5- and 10-year disease-free survival (DFS) were 93% and 67%, respectively, while overall survival (OS) rates were 95% and 75%, respectively. The median DFS for patients with N1, N2, and N3 disease was 149 months (94.2-203.7), 120.1 months (108.2-132.0), and 81.8 months (68.4-131.1), respectively (p < 0.001). The median DFS for the three LNR risk groups (low, intermediate, and high risk) was 148.9 months (95.3-202.6), 118.7 months (99.9-137.7), and 81.8 months (68.2-95.3) respectively. Increasing LNR rate was an independent prognostic factor for DFS, according to multivariate analysis (p < 0.001). Furthermore, the median DFS was 133 months for pathologic N1 patients in the LNR intermediate-high risk group, while the median DFS was not reached in patients with LNR and the pN2 low risk group (p = 0.034).
This study confirms the significance of LNR as a prognostic factor for DFS. The results show that in certain specific subgroups, LNR provides more information than pathologic lymph node counts.
在早期乳腺癌中,腋窝淋巴结在决定疾病预后方面起着关键作用。淋巴结受累率可能是比阳性淋巴结数量更有价值的预后因素。因此,我们旨在评估在早期疾病中,淋巴结比率(LNR)与病理淋巴结计数相比是否是一个更优的预后指标。
我们纳入了2004年至2018年间在土耳其6个医学肿瘤中心接受治疗和随访的3053例非转移性、淋巴结阳性乳腺癌患者。根据LNR,患者被分为三个风险组:高风险组(>0.65)、中风险组(0.21 - 0.65)和低风险组(≤0.20)。
根据基于阳性淋巴结数量的TNM8系统对患者进行分类,结果显示病理淋巴结计数(pN)1占49.0%(n = 1495),pN2占30.0%(n = 917),pN3占21.0%(n = 641)。基于LNR风险组,低风险组占全部患者的45.4%(n = 1385),中风险组占36.2%(n = 1105),高风险组占18.4%(n = 563)。对于整个患者队列,5年和10年无病生存率(DFS)分别为93%和67%,而总生存率(OS)分别为95%和75%。N1、N2和N3期疾病患者的中位DFS分别为149个月(94.2 - 203.7)、120.1个月(108.2 - 132.0)和81.8个月(68.4 - 131.1)(p < 0.001)。三个LNR风险组(低、中、高风险)的中位DFS分别为148.9个月(95.3 - 202.6)、118.7个月(99.9 - 137.7)和81.8个月(68.2 - 95.3)。多因素分析显示,LNR升高是DFS的独立预后因素(p < 0.001)。此外,LNR中高风险组的病理N1患者中位DFS为133个月,而LNR和pN2低风险组患者的中位DFS未达到(p = 0.034)。
本研究证实了LNR作为DFS预后因素的重要性。结果表明,在某些特定亚组中,LNR比病理淋巴结计数提供了更多信息。